Kang YK - Search Results

1

Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW. Llovet JM, et al. Among authors: kang yk. J Clin Oncol. 2013 Oct 1;31(28):3509-16. doi: 10.1200/JCO.2012.47.3009. Epub 2013 Aug 26. J Clin Oncol. 2013. PMID: 23980090 Clinical Trial.

2

Randomized trial of postoperative adjuvant therapy in stage II and III rectal cancer to define the optimal sequence of chemotherapy and radiotherapy: a preliminary report.

Lee JH, Lee JH, Ahn JH, Bahng H, Kim TW, Kang YK, Lee KH, Kim JC, Yu CS, Kim JH, Ahn SD, Kim WK, Kim SH, Lee JS. Lee JH, et al. Among authors: kang yk. J Clin Oncol. 2002 Apr 1;20(7):1751-8. doi: 10.1200/JCO.2002.07.037. J Clin Oncol. 2002. PMID: 11919231 Clinical Trial.

3

Oral doxifluridine plus leucovorin in metastatic colorectal cancer: randomized phase II trial with intravenous 5-fluorouracil plus leucovorin.

Ahn JH, Kim TW, Lee JH, Min YJ, Kim JG, Kim JC, Yu CS, Kim WK, Kang YK, Lee JS. Ahn JH, et al. Among authors: kang yk. Am J Clin Oncol. 2003 Feb;26(1):98-102. doi: 10.1097/01.COC.0000017089.68491.1F. Am J Clin Oncol. 2003. PMID: 12576934 Clinical Trial.

4

Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.

Lee SS, Lee JL, Ryu MH, Chang HM, Kim TW, Kang HJ, Kim WK, Lee JS, Kang YK. Lee SS, et al. Among authors: kang hj, kang yk. Jpn J Clin Oncol. 2007 Jan;37(1):30-7. doi: 10.1093/jjco/hyl134. Jpn J Clin Oncol. 2007. PMID: 17272321

5

Phase II study of biweekly paclitaxel and cisplatin combination chemotherapy in advanced gastric cancer: Korea Japan Collaborative Study Group Trial.

Kim YH, Yamaguchi K, Bang YJ, Takiuchi H, Kang WK, Sato A, Kang YK, Sakamoto J, Abe C, Sakata Y. Kim YH, et al. Among authors: kang wk, kang yk. Jpn J Clin Oncol. 2007 Jul;37(7):501-8. doi: 10.1093/jjco/hym054. Epub 2007 Aug 2. Jpn J Clin Oncol. 2007. PMID: 17673470 Clinical Trial.

6

Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: a retrospective analysis.

Lee JL, Ryu MH, Chang HM, Kim TW, Lee SS, Sym SJ, Kim MK, Kim KM, Lee JS, Kang YK. Lee JL, et al. Among authors: kang yk. J Gastroenterol Hepatol. 2008 May;23(5):811-6. doi: 10.1111/j.1440-1746.2007.05213.x. Epub 2007 Nov 6. J Gastroenterol Hepatol. 2008. PMID: 17995941

7

Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.

Sym SJ, Ryu MH, Lee JL, Chang HM, Kim TW, Lee SS, Lee JS, Kang YK. Sym SJ, et al. Among authors: kang yk. Am J Clin Oncol. 2008 Apr;31(2):151-6. doi: 10.1097/COC.0b013e31815878a2. Am J Clin Oncol. 2008. PMID: 18391599

8

A prospective, multicenter, phase 2 study of imatinib mesylate in korean patients with metastatic or unresectable gastrointestinal stromal tumor.

Ryu MH, Kang WK, Bang YJ, Lee KH, Shin DB, Ryoo BY, Roh JK, Kang JH, Lee H, Kim TW, Chang HM, Park JO, Park YS, Kim TY, Kim MK, Lee WK, Kang HJ, Kang YK. Ryu MH, et al. Among authors: kang jh, kang wk, kang hj, kang yk. Oncology. 2009;76(5):326-32. doi: 10.1159/000209384. Epub 2009 Mar 23. Oncology. 2009. PMID: 19307738 Clinical Trial.

9

The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.

Sohn BS, Kim TW, Lee JL, Ryu MH, Chang HM, Kang YK, Park HS, Na YS, Jang SJ, Kim JC, Lee JS. Sohn BS, et al. Among authors: kang yk. Oncology. 2009;77(3-4):224-30. doi: 10.1159/000236046. Epub 2009 Sep 7. Oncology. 2009. PMID: 19738388

10

Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib.

Yoo C, Ryu MH, Kang BW, Yoon SK, Ryoo BY, Chang HM, Lee JL, Beck MY, Kim TW, Kang YK. Yoo C, et al. Among authors: kang bw, kang yk. J Clin Oncol. 2010 Mar 20;28(9):1554-9. doi: 10.1200/JCO.2009.26.5785. Epub 2010 Feb 22. J Clin Oncol. 2010. PMID: 20177019

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

773 results

Search Page